NEJM Volume 394, Issue 9: February 26, 2026 – Medical Research

The routine scan wasn’t looking for cancer. It was assessing heart health, a follow-up to a mild arrhythmia. But an incidental finding – a shadow on the lung – led to a cascade of investigation that has, for the first time in humans, demonstrated selective reactivation of mutant p53 in advanced solid tumors. The findings, published in the February 26, 2026 issue of The New England Journal of Medicine, detail early data from a Phase 1 trial of the investigational drug rezatapopt.

Unearthing a Hidden Vulnerability

p53 is often called the “guardian of the genome.” It’s a tumor suppressor protein, meaning it normally prevents cells with damaged DNA from growing and dividing. Though, p53 is frequently mutated in cancer – in fact, it’s the most commonly mutated gene in human cancers. These mutations often render p53 non-functional, allowing cancer cells to proliferate unchecked. Rezatapopt, developed by PMV Pharma, aims to restore function to certain mutant forms of p53, effectively re-arming the cell’s own defenses against cancer.

The initial patient in the trial, a 68-year-old man with metastatic non-compact cell lung cancer, had exhausted standard treatment options. The incidental lung nodule, discovered during a cardiac workup, proved to be a particularly aggressive form of the disease. Genetic sequencing revealed a specific p53 mutation – R273H – that rezatapopt is designed to target. The trial, as detailed in the PMV Pharma press release, is designed to assess the safety and tolerability of rezatapopt, as well as to look for early signs of anti-tumor activity.

First-in-Human Data: What the Trial Showed

The published data focuses on the first cohort of patients enrolled in the Phase 1 trial. Even as the primary goal of Phase 1 trials is safety, researchers observed encouraging signals of anti-tumor activity in several patients, including the index case. Specifically, the patient with the R273H p53 mutation experienced a partial response – a measurable reduction in tumor size – after receiving rezatapopt. Further analysis showed that the drug was able to selectively reactivate the mutant p53 protein in tumor cells, restoring its ability to induce cell death.

It’s crucial to understand that What we have is very early data. The trial involved a small number of patients, and the observed responses may not be representative of the broader population of cancer patients with p53 mutations. The study design, as is typical for Phase 1 trials, did not include a control group, making it difficult to definitively attribute the observed effects to rezatapopt. The long-term durability of the responses remains unknown. The NEJM This Week video highlights this trial alongside other recent advances, emphasizing the exploratory nature of these early findings.

The Significance of Mutant p53 and Targeted Therapies

The challenge with targeting p53 has always been its complexity. There are hundreds of different p53 mutations, and not all of them are amenable to reactivation. Rezatapopt is designed to specifically target a subset of these mutations, including R273H, which is found in a significant proportion of cancers. This targeted approach is a key differentiator from previous attempts to restore p53 function, which often lacked specificity and were associated with significant side effects.

The potential impact of successfully reactivating mutant p53 is substantial. If rezatapopt, or similar drugs, can be shown to be safe and effective in larger clinical trials, it could offer a new treatment option for patients with cancers that have historically been difficult to treat. This is particularly relevant for cancers that have developed resistance to other therapies, as restoring p53 function could potentially overcome these resistance mechanisms.

Beyond Rezatapopt: A Broader Landscape of p53 Research

Rezatapopt is not the only drug being developed to target p53. Several other companies and research institutions are pursuing different strategies, including gene therapy approaches and small molecule inhibitors. The growing interest in p53-targeted therapies reflects a broader trend in cancer research towards personalized medicine – tailoring treatment to the specific genetic characteristics of each patient’s tumor. The New England Journal of Medicine’s 2026 issue archive demonstrates a consistent focus on precision oncology, with multiple articles detailing advancements in genomic profiling and targeted therapies.

What Comes Next: Clinical Development and Surveillance

The Phase 1 trial of rezatapopt is ongoing, with additional patients being enrolled to further assess the drug’s safety and efficacy. Researchers are also exploring the potential of combining rezatapopt with other cancer therapies, such as chemotherapy and immunotherapy. If the Phase 1 trial continues to show promising results, the drug could move into Phase 2 and Phase 3 clinical trials, which would involve larger numbers of patients and would be designed to confirm its efficacy and identify the optimal treatment regimen. Regulatory agencies, such as the FDA, will carefully review the data from these trials before deciding whether to approve the drug for widespread use. Ongoing surveillance of patients enrolled in the trial will be critical to monitor for long-term effects and to identify any potential safety concerns.